Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 3
1992 1
1993 1
1994 1
1995 2
1997 3
1998 2
1999 2
2000 3
2001 1
2002 2
2004 3
2005 3
2006 1
2007 2
2008 3
2009 1
2010 2
2011 3
2012 3
2013 3
2015 1
2016 1
2019 2
2020 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
Dubash TD, Bardia A, Chirn B, Reeves BA, LiCausi JA, Burr R, Wittner BS, Rai S, Patel H, Bihani T, Arlt H, Bidard FC, Kaklamani VG, Aftimos P, Cortés J, Scartoni S, Fiascarelli A, Binaschi M, Habboubi N, Iafrate AJ, Toner M, Haber DA, Maheswaran S. Dubash TD, et al. Among authors: binaschi m. Breast Cancer Res Treat. 2023 Aug;201(1):43-56. doi: 10.1007/s10549-023-06998-w. Epub 2023 Jun 15. Breast Cancer Res Treat. 2023. PMID: 37318638 Free PMC article.
Anthracyclines: selected new developments.
Binaschi M, Bigioni M, Cipollone A, Rossi C, Goso C, Maggi CA, Capranico G, Animati F. Binaschi M, et al. Curr Med Chem Anticancer Agents. 2001 Aug;1(2):113-30. doi: 10.2174/1568011013354723. Curr Med Chem Anticancer Agents. 2001. PMID: 12678762 Review.
Histone deacetylase inhibitors: from bench to clinic.
Paris M, Porcelloni M, Binaschi M, Fattori D. Paris M, et al. Among authors: binaschi m. J Med Chem. 2008 Mar 27;51(6):1505-29. doi: 10.1021/jm7011408. Epub 2008 Feb 5. J Med Chem. 2008. PMID: 18247554 Review. No abstract available.
4-N-Hydroxy-4-[1-(sulfonyl)piperidin-4-yl]-butyramides as HDAC inhibitors.
Rossi C, Fincham CI, D'Andrea P, Porcelloni M, Ettorre A, Mauro S, Bigioni M, Binaschi M, Maggi CA, Nardelli F, Parlani M, Fattori D. Rossi C, et al. Among authors: binaschi m. Bioorg Med Chem Lett. 2011 Nov 15;21(22):6767-9. doi: 10.1016/j.bmcl.2011.09.042. Epub 2011 Sep 18. Bioorg Med Chem Lett. 2011. PMID: 21978679
MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.
Merlino G, Fiascarelli A, Bigioni M, Bressan A, Carrisi C, Bellarosa D, Salerno M, Bugianesi R, Manno R, Bernadó Morales C, Arribas J, Dusek RL, Ackroyd JE, Pham PH, Awdew R, Aud D, Trang M, Lynch CM, Terrett J, Wilson KE, Rohlff C, Manzini S, Pellacani A, Binaschi M. Merlino G, et al. Among authors: binaschi m. Mol Cancer Ther. 2019 Sep;18(9):1533-1543. doi: 10.1158/1535-7163.MCT-18-0624. Epub 2019 Jun 21. Mol Cancer Ther. 2019. PMID: 31227646
Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer.
Fiascarelli A, Merlino G, Capano S, Talucci S, Bisignano D, Bressan A, Bellarosa D, Carrisi C, Paoli A, Bigioni M, Tunici P, Irrissuto C, Salerno M, Arribas J, de Stanchina E, Scaltriti M, Binaschi M. Fiascarelli A, et al. Among authors: binaschi m. Breast Cancer Res Treat. 2023 May;199(1):13-23. doi: 10.1007/s10549-023-06895-2. Epub 2023 Mar 13. Breast Cancer Res Treat. 2023. PMID: 36913051 Free PMC article.
52 results